{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:41:44Z","timestamp":1773819704344,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["NIHR300166"],"award-info":[{"award-number":["NIHR300166"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The main aims of therapy in chronic stable angina are to reduce the risk of myocardial infarction and death and improve symptoms and quality of life (QoL). Unblinded trials have shown that revascularization does not reduce the risk of myocardial infarction or death but does appear to improve symptoms. However, symptoms are susceptible to the placebo effect which can bias therapies to appear more effective than they are. To assess the true physical impact of a treatment on symptoms, placebo-controlled trials with patients and medical and research teams blinded to treatment allocation are necessary. Symptoms and QoL can be reported directly by the patient or indirectly by the physician. Patient-reported outcome measures in angina trials can include angina frequency, frequency of nitrate use, exercise capacity, and questionnaires such as the Seattle Angina Questionnaire (SAQ) and the generic EuroQOL-5D-5L (EQ-5D-5L) QoL questionnaire. Physician-assessed outcome measures include Canadian Cardiovascular Society Class. The Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) trial was the first blinded placebo-controlled study investigating the role of percutaneous coronary intervention (PCI) in chronic stable angina. The trial showed a smaller than expected and not statistically significant effect of placebo-controlled PCI on the primary endpoint of change in exercise time at 6 weeks follow-up in single-vessel coronary artery disease. There was also no significant placebo-controlled treatment effect of PCI for the prespecified secondary endpoints of SAQ or EQ-5D-5L, although PCI did result in 20% more patients becoming free from angina than placebo in a non-prespecified secondary analysis. ORBITA has demonstrated the need for symptomatic and QoL effects of PCI to be studied using placebo control. Here, we describe ways of measuring QoL, the impact of the unblinded and blinded trials to date, what we have learned from ORBITA, and what is next for this common and complex condition.<\/jats:p>","DOI":"10.1007\/s10557-021-07198-8","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T04:04:29Z","timestamp":1629518669000},"page":"1011-1018","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Quality of Life Assessment in Trials of Revascularization for Chronic Stable Angina: Insights from ORBITA and the Implications of Blinding"],"prefix":"10.1007","volume":"36","author":[{"given":"Alexandra N","family":"Nowbar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrel P","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha K","family":"Al-Lamee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,21]]},"reference":[{"key":"7198_CR1","unstructured":"Heart Disease and Stroke Statistics\u20142020 Update: A report from the American Heart Association | Circulation [Internet]. [cited 2020 Oct 6]. Available from: https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000000757"},{"issue":"2","key":"7198_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/heart.87.2.140","volume":"87","author":"B Brorsson","year":"2002","unstructured":"Brorsson B, Bernstein SJ, Brook RH, Werk\u00f6 L. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart. 2002;87(2):140\u20135.","journal-title":"Heart."},{"key":"7198_CR3","unstructured":"Initial invasive or conservative strategy for stable coronary disease | NEJM [Internet]. [cited 2020 Oct 6]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa1915922, 382, 1395, 1407"},{"issue":"15","key":"7198_CR4","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503\u201316.","journal-title":"N Engl J Med."},{"issue":"6","key":"7198_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7406","volume":"3","author":"JT Saxon","year":"2020","unstructured":"Saxon JT, Chan PS, Tran AT, Angraal S, Jones PG, Grantham JA, et al. Comparison of patient-reported vs physician-estimated angina in patients undergoing elective and urgent percutaneous coronary intervention. JAMA Netw Open. 2020;3(6):e207406.","journal-title":"JAMA Netw Open."},{"issue":"8845","key":"7198_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/0140-6736(93)90348-K","volume":"341","author":"Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial","year":"1993","unstructured":"Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet Lond Engl. 1993;341(8845):573\u201380.","journal-title":"Lancet Lond Engl"},{"issue":"20","key":"7198_CR7","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","volume":"61","author":"M Kosiborod","year":"2013","unstructured":"Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013;61(20):2038\u201345.","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"7198_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","volume":"48","author":"PH Stone","year":"2006","unstructured":"Stone PH, Gratsiansky NA, Blokhin A, Huang I-Z, Meng L. ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566\u201375.","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"7198_CR9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1067\/mhj.2001.112781","volume":"141","author":"JA Spertus","year":"2001","unstructured":"Spertus JA, Dewhurst T, Dougherty CM, Nichol P. Testing the effectiveness of converting patients to long-acting antianginal medications: the Quality of Life in Angina Research Trial (QUART). Am Heart J. 2001;141(4):550\u20138.","journal-title":"Am Heart J."},{"issue":"1","key":"7198_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychores.2005.12.008","volume":"61","author":"A Appels","year":"2006","unstructured":"Appels A, van Elderen T, B\u00e4r F, van der Pol G, Erdman RAM, Assman M, et al. Effects of a behavioural intervention on quality of life and related variables in angioplasty patients: results of the EXhaustion Intervention Trial. J Psychosom Res. 2006;61(1):1\u20137 discussion 9-10.","journal-title":"J Psychosom Res."},{"issue":"10115","key":"7198_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9","volume":"391","author":"R Al-Lamee","year":"2018","unstructured":"Al-Lamee R, Thompson D, Dehbi H-M, Sen S, Tang K, Davies J, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet Lond Engl. 2018;391(10115):31\u201340.","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"7198_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1089\/jwh.2018.7019","volume":"28","author":"PK Mehta","year":"2019","unstructured":"Mehta PK, Sharma S, Minissian M, Harsch MR, Martinson M, Nyman JA, et al. Ranolazine reduces angina in women with ischemic heart disease: results of an open-label, multicenter trial. J Womens Health 2002. 2019;28(5):573\u201382.","journal-title":"J Womens Health 2002"},{"key":"7198_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/eurheartj\/8.suppl_M.37","volume":"8","author":"MB Maltz","year":"1987","unstructured":"Maltz MB, Dymond DS, Nathan AW, Camm AJ. A comparison of once daily bisoprolol, 5 and 10 mg, and atenolol 100 mg in the treatment of angina pectoris. Eur Heart J. 1987;8:37\u201342.","journal-title":"Eur Heart J"},{"issue":"6","key":"7198_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1161\/CIRCOUTCOMES.113.000752","volume":"7","author":"SV Arnold","year":"2014","unstructured":"Arnold SV, Kosiborod M, Li Y, Jones PG, Yue P, Belardinelli L, et al. Comparison of the Seattle Angina Questionnaire with daily angina diary in the TERISA clinical trial. Circ Cardiovasc Qual Outcomes. 2014;7(6):844\u201350.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"7198_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ahj.2018.04.012","volume":"201","author":"KK Patel","year":"2018","unstructured":"Patel KK, Arnold SV, Chan PS, Tang Y, Jones PG, Guo J, et al. Validation of the Seattle angina questionnaire in women with ischemic heart disease. Am Heart J. 2018;201:117\u201323.","journal-title":"Am Heart J."},{"issue":"3","key":"7198_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/clc.4960140306","volume":"14","author":"I Wiklund","year":"1991","unstructured":"Wiklund I, Comerford MB, Dimen\u00e4s E. The relationship between exercise tolerance and quality of life in angina pectoris. Clin Cardiol. 1991;14(3):204\u20138.","journal-title":"Clin Cardiol."},{"issue":"6","key":"7198_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/heart.83.6.641","volume":"83","author":"M Dempster","year":"2000","unstructured":"Dempster M, Donnelly M. Measuring the health related quality of life of people with ischaemic heart disease. Heart. 2000;83(6):641\u20134.","journal-title":"Heart."},{"issue":"2","key":"7198_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0735-1097(94)00397-9","volume":"25","author":"JA Spertus","year":"1995","unstructured":"Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25(2):333\u201341.","journal-title":"J Am Coll Cardiol."},{"issue":"5","key":"7198_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med."},{"issue":"9","key":"7198_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/0895-4356(91)90070-P","volume":"44","author":"A Nissinen","year":"1991","unstructured":"Nissinen A, Wiklund I, Lahti T, Akkila J, Wilson A, Wahl M, et al. Anti-anginal therapy and quality of life. A comparison of the effects of transdermal nitroglycerin and long-acting oral nitrates. J Clin Epidemiol. 1991;44(9):989\u201397.","journal-title":"J Clin Epidemiol."},{"key":"7198_CR21","first-page":"12","volume":"25","author":"J Wu","year":"2014","unstructured":"Wu J, Han Y, Zhao F-L, Zhou J, Chen Z, Sun H. Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients. Health Qual Life Outcomes [Internet]. 2014;25:12 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4213514\/.","journal-title":"Health Qual Life Outcomes [Internet]"},{"issue":"2","key":"7198_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/00019053-199916020-00003","volume":"16","author":"A Gandjour","year":"1999","unstructured":"Gandjour A, Lauterbach KW. Review of quality-of-life evaluations in patients with angina pectoris. PharmacoEconomics. 1999 Aug 1;16(2):141\u201352.","journal-title":"PharmacoEconomics."},{"issue":"3","key":"7198_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jcin.2014.02.001","volume":"7","author":"SB King","year":"2014","unstructured":"King SB, Dickert NW, Miller FG. Learning from FAME: the need for sham controls in trials of stable coronary disease. JACC Cardiovasc Interv. 2014;7(3):342\u20134.","journal-title":"JACC Cardiovasc Interv."},{"issue":"1","key":"7198_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1056\/NEJM199201023260102","volume":"326","author":"AF Parisi","year":"1992","unstructured":"Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med. 1992;326(1):10\u20136.","journal-title":"N Engl J Med."},{"issue":"7","key":"7198_CR25","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1161\/01.CIR.92.7.1710","volume":"92","author":"WE Strauss","year":"1995","unstructured":"Strauss WE, Fortin T, Hartigan P, Folland ED, Parisi AF. A comparison of quality of life scores in patients with angina pectoris after angioplasty compared with after medical therapy. Outcomes of a randomized clinical trial. Veterans Affairs Study of Angioplasty Compared to Medical Therapy Investigators. Circulation. 1995;92(7):1710\u20139.","journal-title":"Circulation."},{"issue":"7","key":"7198_CR26","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0735-1097(97)00097-1","volume":"29","author":"ED Folland","year":"1997","unstructured":"Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME InvestigatorS. J Am Coll Cardiol. 1997;29(7):1505\u201311.","journal-title":"J Am Coll Cardiol."},{"issue":"7","key":"7198_CR27","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/0735-1097(95)00384-3","volume":"26","author":"WA Hueb","year":"1995","unstructured":"Hueb WA, Bellotti G, de Oliveira SA, Arie S, de Albuquerque CP, Jatene AD, et al. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol. 1995;26(7):1600\u20135.","journal-title":"J Am Coll Cardiol."},{"key":"7198_CR28","doi-asserted-by":"crossref","unstructured":"Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. The Lancet. 1997 Aug 16;350(9076):461\u20138.","DOI":"10.1016\/S0140-6736(97)07298-X"},{"issue":"4","key":"7198_CR29","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0735-1097(99)00637-3","volume":"35","author":"SJ Pocock","year":"2000","unstructured":"Pocock SJ, Henderson RA, Clayton T, Lyman GH, Chamberlain DA. Participants for the R-2 T. Quality of life after coronary angioplasty or continued medical treatment for angina: three-year follow-up in the RITA-2 trial. J Am Coll Cardiol. 2000;35(4):907\u201314.","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"7198_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ijcard.2006.06.001","volume":"116","author":"ME Favarato","year":"2007","unstructured":"Favarato ME, Hueb W, Boden WE, Lopes N, Nogueira CRS da R, Takiuti M, et al. Quality of life in patients with symptomatic multivessel coronary artery disease: a comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial. Int J Cardiol. 2007;116(3):364\u201370.","journal-title":"Int J Cardiol."},{"issue":"7","key":"7198_CR31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMoa072771","volume":"359","author":"WS Weintraub","year":"2008","unstructured":"Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359(7):677\u201387.","journal-title":"N Engl J Med."},{"issue":"5","key":"7198_CR32","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1161\/CIRCULATIONAHA.117.031907","volume":"137","author":"WF Fearon","year":"2018","unstructured":"Fearon WF, Takeshi N, Bernard DB, Boothroyd Derek B, Emanuele B, Pim T, et al. Clinical outcomes and cost-effectiveness of fractional flow reserve\u2013guided percutaneous coronary intervention in patients with stable coronary artery disease. Circulation. 2018;137(5):480\u20137.","journal-title":"Circulation."},{"key":"7198_CR33","doi-asserted-by":"crossref","unstructured":"Spertus JA, Jones PG, Maron DJ, O\u2019Brien SM, Reynolds HR, Rosenberg Y, et al. Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med [Internet]. 2020; Available from: https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1916370.","DOI":"10.1056\/NEJMoa1916370"},{"key":"7198_CR34","unstructured":"Sham Controls in Medical Device Trials | NEJM [Internet]. 2020 https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMp1406388"},{"issue":"17","key":"7198_CR35","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCULATIONAHA.118.033801","volume":"138","author":"R Al-Lamee","year":"2018","unstructured":"Al-Lamee R, Howard JP, Shun-Shin MJ, Thompson D, Dehbi H-M, Sen S, et al. Fractional flow reserve and instantaneous wave-free ratio as predictors of the placebo-controlled response to percutaneous coronary intervention in stable single-vessel coronary artery disease. Circulation. 2018;138(17):1780\u201392.","journal-title":"Circulation."},{"key":"7198_CR36","unstructured":"A placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina - full text view - ClinicalTrials.gov [Internet]. [cited 2019 Aug 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03742050"},{"issue":"22","key":"7198_CR37","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1056\/NEJM195905282602204","volume":"260","author":"LA Cobb","year":"1959","unstructured":"Cobb LA, Thomas GI, Dillard DH, Merendino KA, Bruce RA. An evaluation of internal-mammary-artery ligation by a double-blind technic. N Engl J Med. 1959;260(22):1115\u20138.","journal-title":"N Engl J Med."},{"issue":"10","key":"7198_CR38","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.jacc.2005.06.079","volume":"46","author":"MB Leon","year":"2005","unstructured":"Leon MB, Kornowski R, Downey WE, Weisz G, Baim DS, Bonow RO, et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol. 2005;46(10):1812\u20139.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"7198_CR39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1056\/NEJMoa1402556","volume":"372","author":"S Verheye","year":"2015","unstructured":"Verheye S, Jolic\u0153ur EM, Behan MW, Pettersson T, Sainsbury P, Hill J, et al. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med. 2015;372(6):519\u201327.","journal-title":"N Engl J Med."},{"key":"7198_CR40","unstructured":"Minneapolis Heart Institute Foundation. SHam-controlled INtErvention to improve QOL in CTOs: the SHINE CTO Trial [Internet]. clinicaltrials.gov; 2020 Feb [cited 2020 Oct 5]. Report No.: results\/NCT02784418. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02784418"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07198-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07198-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07198-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T11:27:28Z","timestamp":1664364448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07198-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,21]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["7198"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07198-8","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,21]]},"assertion":[{"value":"26 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human participants performed by any of the authors. In ORBITA, informed consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RAL receives speaker\u2019s honoraria from Phillips Volcano and Menarini Pharmaceuticals. There are no other potential conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}